NCT02317991 2022-07-01Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal CancerSCRI Development Innovations, LLCPhase 2 Completed65 enrolled 11 charts